NeOnc Technologies Holdings Reports Second Quarter 2025 Results and Provides Operational Update

Rhea-AI Summary

NeOnc Technologies (NASDAQ: NTHI), a clinical-stage biotech company focused on CNS cancer therapies, reported Q2 2025 results and significant operational developments. The company secured a $50 million strategic partnership with Quazar Investment and received a $2.5 million NIH grant. Key financial metrics show increased expenses with G&A at $984K (up from $290K) and R&D at $677K (up from $394K), resulting in a net loss of $5.68M.

Clinical progress includes advancing multiple trials: NEO100-01 for malignant gliomas (Phase 2a enrollment expected by September 2025), NEO212 for brain cancer (final Phase I cohort completion in 2025), and NEO100-3 for pediatric indications. The company also acquired an AI and quantum modeling IP portfolio and joined the Russell Microcap® Index.

Positive

• Secured $50 million strategic partnership with Quazar Investment
• Awarded $2.5 million in non-dilutive NIH STTR grants
• Acquired strategic AI, 3D bioprinting, and quantum modeling IP portfolio
• Inclusion in Russell Microcap® Index enhancing institutional visibility
• Multiple clinical trials progressing with key readouts expected by early 2026

Negative

• Increased G&A expenses by 239% year-over-year to $984K
• R&D expenses rose 72% to $677K compared to Q2 2024
• Net loss increased to $5.68M from $4.52M year-over-year
• Higher per-share losses at $0.30 vs $0.27 in Q2 2024

Insights

Biotechnology Analyst

NeOnc secures $50M partnership and advances CNS cancer trials, but widening losses amid increasing operational costs raise execution concerns.

NeOnc's Q2 update reveals significant operational progress across multiple fronts. The $50 million strategic partnership with Quazar Investment is particularly noteworthy as it provides substantial non-dilutive capital for the company's CNS cancer programs while expanding their geographical reach into the GCC & MENA regions. This deal, combined with the $2.5 million in NIH STTR grants, significantly strengthens their cash position without diluting existing shareholders.

On the clinical front, NeOnc is advancing three CNS cancer programs with important near-term catalysts. Their lead program NEO100-01 (intranasal therapy for malignant gliomas) is approaching full Phase 2a enrollment with data expected in early 2026. NEO212 (bio-conjugated therapy) is completing its final Phase I patient cohort, while the pediatric indication trial NEO100-3 has begun recruiting patients. These parallel clinical developments create multiple shots on goal in the challenging CNS oncology space.

The company's financial position shows concerning trends despite the new funding. G&A expenses surged to $984K from $290K year-over-year, a 239% increase, while R&D spending increased to $677K from $394K, up 71.8%. The net loss widened to $5.68M ($0.30/share) from $4.52M ($0.27/share) in Q2 2024. This accelerating cash burn will need monitoring despite the incoming capital infusions.

The acquisition of AI, 3D bioprinting, and quantum modeling IP could potentially enhance their drug development capabilities, though realizing tangible benefits from these technologies typically requires significant additional investment. Their inclusion in the Russell Microcap Index should improve liquidity and institutional visibility, potentially supporting their valuation during key clinical readouts expected through early 2026.

Financial Analyst

NeOnc's $50M partnership bolsters pipeline, but 239% surge in G&A expenses and widening losses highlight significant execution risks.

Looking beyond the optimistic executive commentary, NeOnc's financial metrics reveal concerning trends despite promising business development achievements. The $50 million strategic partnership with Quazar Investment represents a major financial catalyst, providing critical non-dilutive funding for their clinical development pipeline. Similarly, securing $2.5 million in NIH STTR grants demonstrates scientific validation and further extends their financial runway.

However, the company's expenses are escalating at an alarming rate. G&A costs more than tripled to $984K from $290K year-over-year, representing a 239% increase that far outpaces operational expansion. While some of this growth relates to Middle East partnership activities, this dramatic scaling of overhead warrants scrutiny. Similarly, R&D expenses jumped nearly 72% to $677K, reflecting expanded clinical activities across three programs.

The net loss widened to $5.68 million ($0.30 per share) from $4.52 million ($0.27 per share) in Q2 2024, representing a 25.7% increase in net loss. Without the Quazar funding, this burn rate would be unsustainable for an early-stage biotech. The absence of cash position details in this press release is notable, leaving investors unable to calculate their precise runway.

The Russell Microcap Index inclusion should improve liquidity and institutional accessibility, potentially supporting their valuation during upcoming clinical catalysts. The company has positioned multiple near-term milestones through 2026 that could serve as value inflection points, including trial completion and data readouts. However, execution risks remain substantial given the challenging CNS cancer space and rapidly increasing operational costs. Investors should monitor cash burn rates and clinical enrollment progress in upcoming quarters.

CALABASAS, Calif. and ABU DHABI, United Arab Emirates, Aug. 19, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a multi–Phase 2 clinical-stage biotechnology company pioneering therapies for central nervous system (CNS) cancers, today announced financial results for the quarter ended June 30, 2025, and provided an update on recent operational achievements and upcoming milestones.

Second Quarter & Recent Corporate Highlights

• $50 Million Strategic Partnership Secured – All contingencies finalized with Quazar Investment following incorporation of NuroMENA Holdings under Abu Dhabi Global Market (ADGM). This partnership will launch an advanced GCC & MENA clinical trials platform and expand NTHI’s global footprint.
• Non-Dilutive NIH Funding – Awarded $2.5 million in STTR grants to advance NEO212 for gliomas and leukemia, underscoring strong scientific validation and external funding support.
• Technology Expansion – Signed definitive agreement to acquire AI, 3D bioprinting, and quantum modeling IP portfolio from Dr. Ishwar K. Puri.
• Media & Market Visibility –
  
  • Featured on Yahoo Finance’s Trader Talk podcast discussing AI and biotech’s role in brain cancer treatment.
  • Entered a 12-part national TV and media campaign with New to The Street, including commercials, earned media, and billboards.
  • Executive Chairman interviewed live by Kenny Polcari (@Floorstocks).
• Index Inclusion – Joined the Russell Microcap® Index, broadening exposure to institutional investors.
• Clinical Leadership – Appointed Dr. Josh Neman as Chief Clinical Officer to lead clinical strategy and translational oncology programs.
• Strong IP Protection – Global patent portfolio spans all major pharmaceutical markets, covering the company’s core CNS oncology assets.
  

Clinical Pipeline Progress

NEO100-01 – Intranasal therapy for malignant gliomas

• Full Phase 2a enrollment expected by September 2025.
• Top-line data readout anticipated in early 2026.

NEO212 – Bio-conjugated therapy for brain cancer

• Final patient cohort in Phase I on track to complete dosing in 2025.
  

NEO100-3 – Pediatric indication trial initiated with patient recruitment underway.

Financial Results for Q2 2025

• G&A expenses: $984K vs. $290K in Q2 2024, reflecting expanded marketing, rent, travel, and Middle East partnership-related costs.
• R&D expenses: $677K vs. $394K in Q2 2024, driven by additional NEO100 trial sites, increased recruitment for NEO212, initiation of NEO100-3, and overall patient recruitment expansion.
• Net loss: $5.68M or $0.30 per diluted share, compared to $4.52M or $0.27 per diluted share in Q2 2024, primarily due to absence of prior-year financing-related and stock based compensation expenses.
  

Executive Chairman Commentary

Amir Heshmatpour, Executive Chairman and President of NeOnc Technologies Holdings, stated:

“This has been a transformative period for NeOnc. Meeting all the outstanding contingencies for our $50 million strategic partnership with Quazar Investment, being added to the Russell Microcap Index, advancing multiple clinical programs, and acquiring cutting-edge AI and quantum modeling capabilities position us for accelerated growth. We believe these developments not only strengthen our clinical and technological platforms but also create a solid foundation for long-term shareholder value creation. Looking ahead, we expect to have fully enrolled both our NEO100-01 and NEO212 trials before end of 3rd Quarter, with FDA readouts anticipated by the end of 2025 and into the beginning of Q1 2026. Our focus remains on delivering life-changing therapies for patients while executing on strategic initiatives that can significantly expand our market opportunity.”

Upcoming Catalysts

• Q3 2025 – Completion of NEO100-01 Phase 2a enrollment.
• 2025 – Completion of NEO212 Phase I final cohort dosing.
• Early 2026 – NEO100-01 top-line data readout.
• Near-term – Closing and funding of the Quazar Investment $50 million transaction.

About NeOnc Technologies Holdings, Inc.
NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) is a multi–Phase 2 clinical-stage biotechnology company developing novel therapies for brain cancer and other CNS disorders. With a robust intellectual property portfolio, advanced delivery platforms, and collaborations with leading academic centers, NeOnc is committed to transforming outcomes in some of the most difficult-to-treat areas of oncology.

“NEO100” and “NEO212” are registered trademarks of NeOnc Technologies Holdings, Inc.

Company Contact: info@neonc.com
Investor Contact: James Carbonara, Hayden IR – (646) 755-7412 | James@haydenir.com

FAQ

What were NeOnc Technologies (NTHI) key financial results for Q2 2025?

NTHI reported a net loss of $5.68M ($0.30 per share), with G&A expenses of $984K and R&D expenses of $677K. The company secured a $50M strategic partnership and $2.5M in NIH grants.

What are the major clinical trial milestones expected for NTHI in 2025-2026?

NTHI expects to complete NEO100-01 Phase 2a enrollment by September 2025, finish NEO212 Phase I final cohort dosing in 2025, and release NEO100-01 top-line data in early 2026.

How much did NeOnc Technologies' operating expenses increase in Q2 2025?

G&A expenses increased by 239% to $984K from $290K, while R&D expenses rose by 72% to $677K from $394K year-over-year.

What strategic partnerships and grants did NTHI secure in Q2 2025?

NTHI secured a $50 million strategic partnership with Quazar Investment and was awarded $2.5 million in STTR grants from NIH for advancing NEO212 treatments.

What new technological capabilities did NTHI acquire in Q2 2025?

NTHI acquired an IP portfolio including AI, 3D bioprinting, and quantum modeling technologies from Dr. Ishwar K. Puri to enhance their development capabilities.